Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Telecoms, Technology and Oil & Gas sectors led shares lower. At the close in NYSE, the Dow Jones...
CytRx (CYTR) inks an agreement with strategic advisory outfit Destum Partners to help identify partnering opportunities for its LADR (Linker Activated Drug Release) ultra-high...
CytRx (CYTR -6.5%) shareholders have approved a 1:6 reverse split of its common stock, expected to be implemented next week. The action will enable the company to regain compliance...
For Immediate ReleaseChicago, IL – November 12, 2018 - Stocks in this week’s article are Ralph Lauren Corp. (NYSE:RL), The Estee Lauder Companies Inc. (NYSE:EL) , GMS...
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The perception is that the lower the P/E, the higher will be the value of the stock. The simple logic...
The pharma/biotech sector has been struggling so far in 2018. The sector is plagued by several factors, which include drug pricing issues, declining sales of legacy products and...
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology and rare diseases. The Company is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The Company's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol for Niemann Pick disease Type C (NPC) and Gaucher disease.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Neutral | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Neutral | Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 116.00 | 116.63 | 112.92 | +2.32 | +2.04% | 16.68M | NYSE | |||
| 28.68 | 29.81 | 27.65 | -7.01 | -19.64% | 32.87M | NYSE | |||
| 63.54 | 64.54 | 62.21 | -0.13 | -0.20% | 6.57M | NYSE | |||
| 48.14 | 48.14 | 47.08 | +0.81 | +1.71% | 4.09M | NYSE | |||
| 52.31 | 52.37 | 51.25 | -0.12 | -0.23% | 16.06M | NYSE | |||
| 261.01 | 261.63 | 252.00 | +4.73 | +1.85% | 804.48K | NASDAQ | |||
| 23.40 | 24.56 | 22.80 | -1.59 | -6.36% | 3.31M | NASDAQ | |||
| 1.20 | 1.34 | 1.19 | -0.140 | -10.45% | 274.83K | NASDAQ | |||
| 112.81 | 114.30 | 110.22 | +1.86 | +1.68% | 1.52M | NYSE | |||
| 92.43 | 93.56 | 90.07 | +1.33 | +1.46% | 432.98K | NYSE | |||
| 43.28 | 46.29 | 42.48 | -3.95 | -8.36% | 6.75M | NYSE | |||
| 14.09 | 14.12 | 13.69 | +0.30 | +2.18% | 260.19K | NASDAQ | |||
| 8.08 | 8.28 | 7.96 | +0.04 | +0.50% | 225.00K | OTC Markets | |||
| 0.001 | 0.001 | 0.001 | 0.000 | 0.00% | 0.00 | OTC Markets | |||
| 5.00 | 5.00 | 5.00 | 0 | 0.00% | 0.00 | OTC Markets |